Glaukos (NYSE:GKOS) said today that it inked a licensing deal with Intratus for that company’s transdermal drug delivery platform for treating eye conditions.
San Diego-based Intratus developed cream-based drug formulations that are applied to the outer eyelid to treat conditions such as dry eye disease, glaucoma, allergy, blepharitis and conjunctivitis. The deal gives San Clemente, Calif.-based Glaukos exclusive rights to the technology for treating glaucoma and corneal disorders in return for an undisclosed amount.
Get the full story at our sister site, Drug Delivery Business News